Andrew S. Hanzlicek

Dr. Andrew S. Hanzlicek


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
DLDana N. LeVine
Dana N. LeVine
LKLinda Kidd
Linda Kidd
OGOliver A. Garden
Oliver A. Garden
MBMarjory B. Brooks
Marjory B. Brooks
RGRobert Goggs
Robert Goggs
Eva SpadaEva Spada
Eva Spada
Immune thrombocytopenia (ITP) is the most common acquired primary hemostatic disorder in dogs. Immune thrombocytopenia less commonly affects cats but is an important cause of mortality and treatment-associated morbidity in both species. Immune thrombocytopenia remains a diagnosis of exclusion for which diagnostic guidelines are lacking. Primary, or non-associative, ITP refers to autoimmune platelet destruction. Secondary, or associative, ITP arises in response to an underlying disease trigger. However, evidence for which comorbidities serve as ITP triggers has not been systematically evaluated. To identify key diagnostic steps for ITP and important comorbidities associated with secondary ITP, we developed 12 Population Evaluation/Exposure Comparison Outcome (PECO) format questions. These questions were addressed by evidence evaluators utilizing a literature pool of 287 articles identified by the panelists using a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations that then were integrated by diagnosis and comorbidity domain chairs. The revised PECO responses underwent a Delphi survey process to reach consensus on final guidelines. A combination of panel expertise and PECO responses were employed to develop algorithms for diagnosis of ITP in dogs and cats, which also underwent 4 iterations of Delphi review. Comorbidity evidence evaluators employed an integrated measure of evidence (IME) tool to determine evidence quality for each comorbidity; IME values combined with evidence summaries for each comorbidity were integrated to develop ITP screening recommendations, which also were subjected to Delphi review. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The final consensus statement provides clinical guidelines for the diagnosis of, and underlying disease screening for, ITP in dogs and cats. The systematic consensus process identified numerous knowledge gaps that should guide future studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Treatment of Immune Thrombocytopenia.

1 December 2012 in Journal of Veterinary Cardiology
Verified
Journal Article
Closed access
AHAndrew S. Hanzlicek
Andrew S. Hanzlicek
RGRonette Gehring
Ronette Gehring
BKButch KuKanich
Butch KuKanich
KKKate S. KuKanich
Kate S. KuKanich
MBMichele Borgarelli
Michele Borgarelli
MMMarco Margiocco
Marco Margiocco

1 July 2016 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
AHAndrew S. Hanzlicek
Andrew S. Hanzlicek
JMJ.H. Meinkoth
J.H. Meinkoth
JRJ.S. Renschler
J.S. Renschler
CGC. Goad
C. Goad
LWL.J. Wheat
L.J. Wheat
Background: Treatment monitoring is subjective and disease relapse is common in cats with histoplasmosis. The Histoplasma antigen enzyme immunoassay (EIA) is a noninvasive test used for determining disease remission and detecting disease relapse in humans with histoplasmosis. The utility of the antigen EIA for these purposes in cats remains unknown. Hypothesis/Objectives: Those Histoplasma antigen concentrations in urine and serum would decline with antifungal treatment and that antigen elimination would be an indicator of clinical remission in cats with histoplasmosis treated with antifungal treatment. Animals: Fifteen client-owned cats with histoplasmosis. Methods: Masked observational study. Cats were monitored monthly during antifungal treatment. Time of clinical remission and serum and urine antigen elimination were determined for each cat. Results: Twelve of 15 cats achieved clinical remission. At the time of diagnosis, antigen was detectable in urine in 14/15 (93%) cats and in serum in 11/15 (73%) cats. Both serum (P < .0005) and urine (P < .0001) antigen concentrations significantly decreased over time with effective treatment. Antigen elimination was sensitive [urine, 90.0% (95% CI 72.3–97.4%); serum, 90.4% (68.2–98.3%)] but less specific [urine, 64.6% (51.7–75.8%); serum, 52.1% (37.4–66.5%)] for disease remission. Urine antigen was positive in both cats and serum antigen was positive in 1 cat at the time of disease relapse. Conclusions and Clinical Importance: Measurement of Histoplasma antigen in urine and serum might be useful tests for determining disease remission and relapse in cats with histoplasmosis. Further research is needed to investigate the importance of low-level antigenemia and antigenuria.

19 December 2017 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Closed access
HLHilary C Ludwig
Hilary C Ludwig
AHAndrew S. Hanzlicek
Andrew S. Hanzlicek
KKKate S KuKanich
Kate S KuKanich
MPMark E Payton
Mark E Payton
Objectives: The aim of this study was to retrospectively identify candidate prognostic indicators in cats with histoplasmosis treated with antifungal therapy. Methods: Medical records of cats diagnosed with histoplasmosis were reviewed. Candidate prognostic indicators were assessed for an association with survival to hospital discharge and survival to 1 and 6 months after diagnosis. Potential indicators included easily obtained data at the time of the initial hospital visit derived from cat signalment, historical information, physical examination, laboratory data, form of disease and initial treatment. Results: Approximately 88% of cats survived to discharge, with 77% and 67% surviving to 1 and 6 months, respectively. Clinical variables significantly associated with death at more than one outcome time point included the presence of dyspnea, adventitial lung sounds, fungemia, neurologic disease, neutropenia, lymphopenia, multiple cytopenias (anemia, neutropenia, thrombocytopenia), hyperbilirubinemia and increased creatinine kinase activity. Cats that did not survive were more likely to have received corticosteroids, oxygen supplementation and required hospitalization. In addition, cats that did not survive required significantly longer hospitalization. There was no significant difference between initial antifungal drug and survival. Conclusions and relevance: Potential prognostic indicators were associated with more severe respiratory, hepatic, hematologic or neurologic disease. Prospective investigation concerning clinical indicators of disease severity of these body systems is indicated.

23 January 2012 in Journal of Feline Medicine and Surgery
Verified
Journal Article
Closed access
AHAndrew S. Hanzlicek
Andrew S. Hanzlicek
CGChanran Ganta
Chanran Ganta
CMCarl B Myers
Carl B Myers
GGGregory F Grauer
Gregory F Grauer
Two 12-year-old cats were diagnosed with chronic kidney disease (CKD) based on physical examination, clinicopathologic data and, in one case, abdominal ultrasound findings. Approximately 1 year after the initial diagnosis of CKD both cats developed renal transitional cell carcinoma (TCC) — bilateral in one cat. Based on post-mortem examination, one cat had no evidence of metastasis and the other had metastasis to the large intestine, heart and lungs. This is the first report of de novo bilateral renal TCC in a cat, as well as the first report of renal TCC developing in cats with previous history of confirmed CKD.

17 December 2018 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
LRLana Rothenburg
Lana Rothenburg
AHAndrew S. Hanzlicek
Andrew S. Hanzlicek
MPMark E. Payton
Mark E. Payton
Background An in‐house Histoplasma urine antigen test for cats might be desirable in certain situations. Objective To validate and compare the diagnostic performance of a monoclonal antibody‐based IMMY urine Histoplasma antigen enzyme immunoassay (IMMY EIA) to the commercially available urine Histoplasma antigen enzyme immunoassay (MiraVista Diagnostics, MV EIA). Animals One hundred ninety‐three urine samples from 105 client‐owned and purpose‐bred research cats. Methods Cats were classified as Histoplasma positive or negative based on diagnostic investigation. The IMMY EIA and MV EIA were performed on all urine samples. Correlation and agreement between the assays were determined. Diagnostic performance was determined and compared between assays. Results The IMMY EIA, with a 0.25 ng/mL diagnostic cutoff, provided a diagnostic sensitivity (DSe), diagnostic specificity (DSp), and diagnostic accuracy (DAc) of 89% (95% confidence interval [CI]; 73%‐97%), 80% (67%‐89%), and 83% (74%‐90%), respectively. The IMMY EIA, with a 1.1 ng/mL diagnostic cutoff, provided a DSe, DSp, and DAc of 77% (95% CI 60%‐90%), 97% (88%‐100%), and 89% (81%‐95%), respectively. The MV EIA provided a DSe, DSp, and DAc of 94% (95% CI 81%‐99%), 97% (89%‐100%), and 96% (90%‐99%), respectively. Moderate overall agreement was found between MV EIA and IMMY EIA using the 0.25 ng/mL cut‐off (к = 0.44; 95% CI 0.31‐0.57) and the 1.1 ng/mL cut‐off (к = 0.43, 95% CI, 0.31‐0.56). Conclusions and Clinical Importance The IMMY EIA might be useful as a diagnostic test for histoplasmosis in cats. Further modifications of the IMMY EIA are required to achieve the diagnostic performance of the MV EIA.